At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 51 enrolled
Drug / intervention
Mirikizumab - IV +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Mirikizumab - IV, Mirikizumab - SC, and 2 other interventions for Healthy. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartDec 2015
Primary CompletionJul 2018
Study CompletionOct 2018
TodayJul 2026
First PostedOct 5, 2015
Enrollment StartDec 2, 2015
Primary CompletionJul 16, 2018
Study CompletionOct 24, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.7 years ago
Interventions
Mirikizumab - IVdrug
Administered IV
Mirikizumab - SCdrug
Administered SC
Placebo - IVdrug
Administered IV
Placebo - SCdrug
Administered SC